EARLY ADMINISTRATION OF ERYTHROPOIETIN IN EXTREMELY VERY LOW BIRTH WEIGHT PRETERMS

Mihaela Demetrian1, MD, Andreea Avramescu1, MD, Roxana Iliescu1, MD, Andra Pirnuta1, Alcăsandra Ana Irimie2, Vlad Dima1, MD

1 Clinical Hospital of Obstetric „Filantropia”, Bucharest, Romania
2 School of Sociology and Social Work, University of Bucharest, Romania

ABSTRACT

Objectives. The present study is trying to ascertain if EPO can be administered “early” (before 8 days of life) to prevent or reduce the need for blood transfusions. As secondary objectives we aim to observe efficiency and safety when using early EPO with regards to reducing specific ELBW comorbidities.

Methodology. Prospective, randomised clinical study, that included 109 preterm babies with GA 30 wk, and BW 1,250 g, born in our unit between January 2018 and June 2019. The treatment we used was early EPO within the first seven days of life, concomitent an oral iron supplement. According erythropoietin therapy, preterms were randomised in EPO group (n – 40) and control group (n – 69).

Results. During hospitalization, there were 51 blood transfusions in the two groups: 13 in the EPO group and 38 in the control group. As for blood transfusions mean, it was 1.1±0.7 for the EPO group (1-3) versus 1.5±1.2 (1-6) for the control group, p 0.25. There were statistically significant differences between the blood transfusions mean volume in the two groups 35.4±19.3 ml for the EPO group versus 53.5±23.8 ml for the control group, p 0.045. There were no significant differences in IVH incidence (> gr. 3) between the two groups. Fisher’s exact test showed that there was no influence of EPO on brain hemorrhage (X² = 0.86, p = 0.38), intestinal tract (X² = 2.89, p = 1.23), lung tissue (X² = 0.7, p = 1), or the incidence of retinopathy of prematurity (X² = 0.42, p = 0.59).

Conclusions. In our study, the early initiation of erythropoietin (EPO) at less than eight days, reduced the need for transfusions by 0.5 transfusions/patient. The total volume (ml/kg/patient) of transfused blood was reduced by 18 ml. Although the results from the recent meta-analyses showed a moderate quality of evidence that EPO reduces intraventricular hemorrhage (IVH), periventricular leukomalacia (PVL) and NEC, the results of our study did not prove this.

Keywords: anemia of prematurity, early erythropoietin, transfusions

INTRODUCTION AND STUDY PURPOSES

PRBC transfusions continue to be an ongoing debate subject amongst neonatologists. Controversies arise mostly about the timing or opportunity of transfusion, applying a liberal or more restrictive guidelines and short or long time effects. However, 80% of VLBW preterms will receive at least one blood transfusion by the end of hospital stay because of frequent blood sampling or anemia of prematurity. Most transfusions happen in the first three to four weeks of life. Old and stable preterms respond better to EPO and will receive few transfusions. ELBW preterms, that are sick and need blood transfusions shortly after birth, respond inconsistently to EPO. This suggests that EPO is a stronger erythropoietic stimulant in more mature preterms. ELBW preterms are more susceptible to transfusions even with EPO stimulated erythropoiesis (1). Furthermore, ELBW preterms have a smaller blood volume, and repeated blood sampling often require “early” transfusions, as opposed to “late” transfusions that are more characteristic to anemia of prematurity (2). Low serum erythropoietin levels in premature babies offer a good motivation for the use of EPO to prevent or treat anemia. For a better documentation, we accessed the Cochrane Database of Systematic Reviews, the keywords being early EPO administration in VLBW babies. Several study meta-analyses exist, the last one dating from 2017 (3). This meta-analysis also studied the non-hematological effects of erythropoietin therapy and concluded that early EPO administration reduces the number of transfusions, the volume of blood needed and multiple donor exposure. However, the differences between the EPO and the control group were minimal and with limited clinical importance. Mortality
and morbidity rates, including IVH and NEC, were not significantly modified by early EPO therapy.

OBJECTIVES

The present study is trying to ascertain if EPO can be administered "early" (before 8 days of life) to prevent or reduce the need for blood transfusions. Unlike late EPO treatment, there are better odds that the premature babies wouldn’t have received any transfusion before entering the study. As secondary objectives we aim to observe efficiency and safety when using early EPO with regards to reducing neurological injuries and feeding intolerance/NEC; also we aim to observe if early use can influence specific ELBW comorbidities (retinopathy of prematurity ROP, bronchopulmonary dysplasia BPD).

METHODOLOGY

The present study included 109 preterm babies with GA ≤ 30 wk, and BW ≤ 1,250 g, born between January 2018 and June 2019 (18 months) in our unit. Depending on EPO administration, the patients were randomised in two groups: the EPO group and the control group. Inclusion criteria: GA ≤ 30 wk and BW ≤ 1,250 g. Exclusion criteria: congenital malformation/genetic syndromes, TORCH, severe birth asphyxia, IVH > grade 3, Rhesus hemolytic disease. For all preterms we employed strategies to minimise blood loss and reduce multiple donor exposure: delayed cord clamping, minimising blood sampling, and good adherence to transfusion guidelines. The treatment we used was "early" EPO within the first seven days of life. (4). Treatment plan: Binocrit (Epoetin alfa) prefilled syringes, 1000 IU/ml; dosage 400 IU/kg/dose, (3 times a wk), subcutaneous. The length of therapy was 6 weeks, every patients receiving approximately 18 doses of EPO.

Oral iron supplements were initiated when enteral nutrition reached 75% of daily needs, or 60 ml/kg/day. The preferred dosage: was 6 mg/kg/day, which could be increased up to 8-10 mg/kg/day when plasmatic iron levels dropped below 60 mg/dl.

We monitored weekly CBC and serum iron levels. We kept records of: blood amounts needed for laboratory tests, number of PRBC transfusions, the volume of blood transfused, the postnatal age (days) and the target value of hemoglobin and hematocrit for the first transfusion. For all preterms we employed strategies to minimise blood loss and reduce multiple donor exposure: delayed cord clamping, minimising blood sampling, and good adherence to transfusion guidelines. The treatment we used was "early" EPO within the first seven days of life. (4). Treatment plan: Binocrit (Epoetin alfa) prefilled syringes, 1000 IU/ml; dosage 400 IU/kg/dose, (3 times a wk), subcutaneous. The length of therapy was 6 weeks, every patients receiving approximately 18 doses of EPO.

Oral iron supplements were initiated when enteral nutrition reached 75% of daily needs, or 60 ml/kg/day. The preferred dosage: was 6 mg/kg/day, which could be increased up to 8-10 mg/kg/day when plasmatic iron levels dropped below 60 mg/dl.

We monitored weekly CBC and serum iron levels. We kept records of: blood amounts needed for laboratory tests, number of PRBC transfusions, the volume of blood transfused, the postnatal age (days) and the target value of hemoglobin and hematocrit for the first transfusion. Also, we looked for potential nonerythropoietic effects of EPO therapy. The gut trophic and protector effect was evaluated by: onset of enteral nutrition, the amount of proteins/calories at 14 days, clinical aspects of NEC (Bell classification grade > 2). The neuroprotection effect was evaluated by: cerebral lesions like IVH and PVL (4,5). All patients were included in the screening for retinopathy of prematurity (ROP) (6,7). The study was approved by the unit’s Board of Ethics and parents gave consent for EPO and/or blood transfusion. All the data were collected with Epi Info 7 and were processed in the Analysis segment.

RESULTS

We included 116 preterms and collected data for 109 of them: 40 have received EPO therapy in the first week of life, and 69 of them received only oral iron supplements. Gestational age varied between 23-30 wk (27.4±1.8 EPO group vs 28.6±1.9 – control group), and BW between 550 and 1,300 grams (mean 969±186 EPO group vs. 1,096±275 grams control group).

The compared data between two groups are shown in table 1. The EPO group all needed mechanical ventilation and developed more severe forms of RDS. 33 preterms from the EPO group (75%) needed surfactant therapy and from the control group only 30 (42%), p = 0.001. Minimally invasive surfactant administration (LISA/INSURE) was predominant in the control group (65% vs 18%). In the EPO group invasive ventilation and increased MV period were more frequent: mean 13.1 vs 9.5 days, p = 0.21. The EPO group had more severe forms of RDS, more frequent hemodynamic instability, and required increased inotropic support: 67.5% vs 27.5%, p = 0.0034. Although oxygen therapy length in the EPO group was higher (mean 36.3 vs 26.9 days), the incidence of BPD wasn’t significantly different between the two groups: 12.5% (EPO) vs 14.3% (control), p = 0.77. There were no notable differences nutritional-wise: enteral nutrition onset happened generally in the first two days of life (1.6 vs 1.8 days) with a mean parenteral nutrition length of ten days, calorile intake was similar (135 cal/kg), but with a higher weight gain in the control group (114 vs. 93 grams) at 14 days of life, p = 0.05.

Hemoglobin and hematocrit curves

We observed a more abrupt fall in hemoglobin and hematocrit in the control group beginning with week 4 of life (~28 days) up to week 7, the values being equal at discharge. The same evolution was observed hematocrit – wise (6). A split-plot ANOVA showed that the difference between Hb1 and Hb10 dropped significantly in the control group vs the EPO group (F = 6.92, p = 0.01). Another test split plot ANOVA showed that the difference between Hct 10 (at discharge) and Hct 1 (at birth) drop was significantly higher in the control group vs the EPO group (F= 9.64, p = 0.00) (see Fig.1, Fig. 2, Fig. 3, Fig. 4). The mean corpuscular volumes curves followed the same pattern: high volume at birth (115-117 pg) that decreased

![Image](image_url)
with postnatal age. There were no differences between the evolution of MCV in the two groups, corresponding with literature available data (8).

Blood transfusions. During hospitalization, there were 51 blood transfusions in the two groups: 13 in the EPO group and 38 in the control group. The post-

**FIGURE 1.** Hemoglobin curves in two groups

**FIGURE 2.** Split-plot Anova – Hemoglobin variations in two groups

**FIGURE 3.** Hematocrit curves in two groups
nate the first transfusion was given was approx 35 days with a variation of 1-88 days, and was not significantly different in the two groups (29.3±23.5 EPO versus 37.1±19.7 days control group) p 0.25.

Because the same transfusion guideline was applied, there were no significant differences hematocrit and hemoglobin – wise: 8.2±2 versus 7.7±1.5 g/dl, p 0.18 and 27.3 versus 23.5±4.8%, p 0.73.

**Red blood cell transfusions**

During the hospitalization, there were 51 transfusions in the two groups: 13 in the EPO group and 38

**TABLE 1. Demographic and clinical characteristics of the two groups**

| Variables                                | EPO group (n-40) | Control group (n-69) | P value |
|------------------------------------------|------------------|----------------------|---------|
| Gestational age (wk)                     | 27±1.8 (23-30)   | 28±1.9 (24-30)       | 0.08    |
| Birth weight (g)                         | 969±43 (650-1,300)| 1,096±27 (550-1,250) | 0.05    |
| Corticosteroids prophylaxis              | 65% (26)         | 59% (41)             | 0.58    |
| C-section (%)                            | 76% (30/40)      | 60% (40/71)          | 0.08    |
| Preeclampsia (%)                         | 13% (5)          | 39% (13)             | 0.11    |
| Chorioamnionitis                         | 12% (4)          | 10% (7)              | 0.4     |
| Apgar score at 5 min                     | 6.6±1.3          | 6.4±1                | 0.44    |
| Mechanical ventilation                   | 84.3% (59)       | 100% (40)            | 0.07    |
| Non-invasive ventilation (SNIPPV*)       | 55.9% (33)       | 25% (10)             | 0.01    |
| Surfactant                               | 30 (75%)         | 30 (42%)             | 0.001   |
| LISA/INSURE**                            | 18% (5)          | 65% (19)             | 0.01    |
| Mechanical ventilation length (days)     | 13.1±1.3 (2-39)  | 9.5±1.7 (2-70)       | 0.21    |
| Oxygen therapy length (days)             | 36.3±4.8 (1-94)  | 26.9±4.3 (1-117)     | 0.06    |
| Inotropes                                | 67.5% (27)       | 27.5% (19)           | 0.0034  |
| Persistent ductus arteriosus treated with Pedea | 15% (6)      | 20% (14)              | 0.65    |
| Bronchopulmonary dysplasia               | 14.3% (10)       | 12.5% (5)            | 0.77    |
| Enteral nutrition onset (days)            | 1.6±1            | 1.8±1.7              | 0.54    |
| Parenteral nutrition length (days)        | 10.7±5.6         | 9.1±5.2              | 0.09    |
| Calorie/kg at 14 days of life            | 136.3±26         | 134±21               | 0.70    |
| Protein intake at 14 days of life (g/kg/day) | 3.3±0.4   | 3.3±0.5              | 0.86    |
| Weight increase at 14 days of life (grams) | 93±34        | 114±88               | 0.05    |
| Early onset sepsis                       | 28% (11)         | 55% (37)             | 0.02    |
| Late onset sepsis                        | 18% (7)          | 10.4% (7)            | 0.75    |
| Hospitalization length                   | 67.7±17          | 63.9±24              | 0.40    |

*SNIPPV* – synchronous nasal intermittent positive pressure ventilation, **LISA** – low invasive surfactant administration, INSURE – intubation-surfactant-extubation
in the control group. The postnatal age at which the first transfusion was administered was approximately 35 days, with a variation of 1-88 days, and did not differ significantly between the two groups (29.3 ± 23.5 EPO versus 37.1 ± 19.7 days control group), p = 0.25.

Because the same transfusion protocol was applied, hemoglobin and hematocrit values did not have significant differences between the two groups: 8.2 ± 2 versus 7.7 ± 1.5 g/dl, p = 0.18 and 27.3 versus 23.5 ± 4.8%, p = 0.73.

As for blood transfusions mean, it was 1.1±0.7 for the EPO group (1-13) versus 1.5±1.2 (1-6) for the control group, p = 0.25. A Man-Whitney U test showed that there was no statistically significant difference between the blood transfusions mean number in the EPO group (Md = 1, n = 13) and the one in the control group (Md = 1.5, n = 38). There were statistically significant differences between the blood transfusions mean volume in the two groups 35.4±19.3 ml for the EPO group versus 53.5±23.8 ml for the control group, p 0.045. By applying a Mann-Whitney U test we demonstrated a statistically significant difference between the blood transfusions mean number in the two groups (22.4±7.5 EPO group vs 19.2±5.7, control group, p = 0.1). Most transfusions were administered after 28 days of life in both groups.

The non-erythropoietic effects of EPO

One of the proposed scopes of the study was to observe the effect of erythropoietin on intraventricular bleeds, considering its neuroprotection effect. There were no significant differences of IVH (≥ grade 3) and PVL incidence in the two groups. An exact Fisher test showed that there was no influence of EPO in the onset of brain hemorrhages (X² = 0.86, p = 0.38).

Also, we could not demonstrate the protector effect of EPO on the gut mucosa: 2 patients from the EPO group (5%) and 11 from the control group (16%) presented NEC, stages 1 and 2. The exact Fisher test showed that there was no EPO influence over the gut mucosa (X² = 2.89, p = 1.23), the pulmonary tissue (X² = 0.7, p = 1), or ROP incidence (X² = 0.42, p = 0.59) – table no 2.

Severe ROP (> grade 3) and NEC incidence in our study could not be correlated with blood transfusions number (p = 0.88), volume (p = 0.71) and postnatal age (p = 0.88) when blood transfusions where given (9).

As for blood transfusions number (p 0.88), volume (p = 0.71) and postnatal age (p = 0.88) when blood transfusions where given (9).

| Variables                              | EPO group | Control group | Exact Fisher test | P value |
|----------------------------------------|-----------|---------------|-------------------|---------|
| Incidence of cerebral lesions          | 3.5% (3)  | 5.5% (6)      | X² = 0.86         | 0.38    |
| of IVH > gr. 3, PVL                    |           |               |                   |         |
| Incidence of ROP > gr. 3               | 5.2% (2)  | 1.64% (1)     | X² = 0.42         | 0.59    |
| Incidence of NEC std. 1-2              | 5.1% (2)  | 15.9% (11)    | X² = 2.89         | 1.23    |
| Incidence of BPD                       | 12.5% (5) | 14.3% (10)    | X² = 0.7          | 1       |

DISCUSSIONS

In our study, early EPO use in the first 8 days of life, reduced the need for transfusion by 0.5/patient. The total blood transfusion volume (ml/kg/patient) was reduced, as well as donor numbers amongst the randomized patients – but not for the transfused preterms. This facts are consistent with the study meta-analysis regarding „early” EPO administration (3) which concluded that EPO significantly reduces the number of transfusions by one or more/patient, the volume of transfused blood and the number of multiple donor exposures. For all these results, the effect size was small and susceptible to limited clinical importance. Although the two groups were equal from a demographic point of view, the respiratory pathology in the EPO group was more severe, and so it was expected that the transfusional needs would be higher in these cases (10). It is possible that this difference in respiratory pathology between the two groups has influenced the EPO therapy results. In general, for these preterms, PRBC transfusions provide a certain hemoglobin level that depends on the level of cardiac and respiratory support required. For ELBW preterms, almost half of PRBC transfusions are administered in the first two weeks of life, when cardiac and respiratory pathologies are more severe and blood sampling more frequent; in the first week of life, losses through blood
sampling can reach 10-30% of total blood volume (10-25 ml/kg) (11). In our study we could not prove the effect of erythropoietin in neuroprotection; the number of patients with cerebral lesions (IVH > gr. 3) was very low in the two groups and it is hard to significantly correlate statistically. In the latest meta-analysis review on EPO studies, the incidence of IVH (grade 3 and 4) and PVL dropped significantly. Regarding ROP, we did not observe any aggressive forms, although there have been studies which demonstrated a significant increase of ROP (>grade 3) rate, when administering early EPO (6). At the same time, PRBC transfusion in the first 10 days of life was associated with a 4-fold increase of severe retinopathy risk, regardless of gestational age or bronchopulmonary dysplasia (9-11). The protective effects of erythropoietin on the gut mucosa could not be proven in our study. There were only mild forms of NEC (stages 1 and 2) and it was difficult to achieve a correlation with the protective effect of EPO vs PRBC transfusions. Oxygen alteration or disruption of mezenteric perfusion were implicated in the phenomenon know as TRAG – transfusion related acute injury of gut (12-16). Although the results related to the transfusion impact of these meta-analyses cannot recommend, at the moment, the use of EPO in the standard treatment of prematurity anemia, its non-erythropoietic effects (especially neuroprotection) represent a promise and a challenge to continue further studies (17).

CONCLUSIONS

In our study, the early use of EPO in the first 8 days of life reduced the need for blood transfusions by 0.5/patient. The total transfusion volume (ml/kg/patient) was reduced by 18 ml. Early EPO use can reduce the number of transfusions by one or more/patient, the volume of blood needed is smaller, as well as the number of donors/patient. Although statistically significant, these reductions have limited clinical importance. In our study, like in the current meta-analyses updates for early EPO use, with high quality evidence according to GRADE, there is no significant increase of ROP (≥ grade 3) rate. Although recent meta-analyses results showed (moderate quality evidence) that EPO reduces IVH, PVL and NEC incidence, our study did not demonstrate this aspect.

REFERENCES

1. Kotto-Kome AC, Garcia MG, Calhouna DA, Christensen RD. Effect of beginning recombinant erythropoietin treatment within the first week of life, among very-low-birth-weight neonates, on "early" and "late" erythropoietin transffuses a meta-analysis. Journal of Perinatology 2004; 24(1): 24-9.
2. Garcia MG, Hutson AD, Christensen RD. Effect of recombinant erythropoietin on "late" transfusion in the neonatal intensive care unit: A meta-analysis. Journal of Perinatology 2002;22(2);108-11.
3. Ohlsson A, Aher SM. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews 2014, Up-Date 2017, Issue 4. Art. No.: CD004863.
4. Juul S. Neuroprotective role of erythropoietin in neonates. Journal of Maternal-Fetal & Neonatal Medicine 2012; 25 (Suppl 4):105-7.
5. Jakab A., Ruegger C., Bucher HU, Makki M, Huppi PS,Hagmann C, Swis EPO Neuroprotection Trial Group Network based statistics reveals trophic and neuroprotective effect of early high dose erythropoietin on brain connectivity in very preterm infants. Neuroimaj. Clin 2019; 22: 101806 Epub 2019 Apr 1.
6. Ohlsson, Aher SM. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2012 Sep 12 .(9): CD004863.
7. Fierson WM. American Academy of Pediatrics Section on O, American Academy of O, American Association for Pediatric O, Strabismus, American Association of Certified O. Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2013; 131:189-95.
8. Robert D. Christensen, MD, Erick Henry, MPH, Jeff Jopling, BS, and Susan E. Wiedmeier, MD The CBC: Reference Ranges for Neonates, Seminars in Perinatology, 2009 Elsevier.
9. Lust C, Vesouli Z, Jackups R, Liao S, Rao R, Malthur AM. Early red cell transfusion is associated with development of severe retinopathy of prematurity. J Perinatol. 2019, Mar, 39(3):393-400.
10. Howarth C, Banerjee I, Aladangady N. Red blood cell transfusions in preterm infants: current evidence and controversies. Neonatology 2018; 114:7-16.
11. Wang Y, Chan O, Chiang M, Yang P. Red Blood Cell Transfusion and Clinical Outcomes in Extremely Low Birth Weight Preterm Infants. Pediatric Neonatol. 2017; 58(3):216. Epub 2016 Jul 5.
12. Dani C, Poggi C, Gozzini E, Leonardi V, Sereni A, Abbate R, Gori AM: Red blood cell transfusions can induce proinflammatorcy cytokines in preterm infants. Transfusian 2017; 57: 1304-1310.
13. Song J, Sun H, Xu F, Kang W. Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Ann Neural. 2016 Jul;80(1):24-34.
14. J. Blau, JM Calo, D Dozor, M Sutton, G Alpan, EF La Gamma. Transfusion-related acute gut injury: Necrotizing enterocolitis in very low birth weight neonates after packed red blood cell transfusion. J Pediatr, 2015; 165 (2014), pp. 678-682.
15. PB Wallenstein, YH Araith, KL Binnie, J Andrews, JP Palma, WE Benitz et al. Red blood cell transfusion is not associated with necrotizing enterocolitis: A review of consecutive transfusions in a tertiary neonatal intensive care unit. J Pediatr; 165 (2014), pp. 678-682.
16. Patel RM, Knezevic A, Shenvi N, Hinkes M, Keene S, Roback JD, Easley KA, Josephson CD. Association of red blood cell transfusion, anemia, and necrotizing enterocolitis in very low-birth-weight infants. JAMA 2016; 315: 889-897.
17. Aher SM, Ohlsson A. Late erythropoiesis-stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants. Cochrane Database Syst Rev. 2019;2.